<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40455462</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>808</StartPage><EndPage>816</EndPage><MedlinePgn>808-816</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2025.1359</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">A recent study reported that methotrexate may reduce joint pain in patients with inflammatory hand osteoarthritis (OA). However, it remains unknown whether methotrexate has similar effects on inflammatory knee OA.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To examine whether methotrexate has symptom-relieving and disease-modifying effects for participants with knee OA and effusion-synovitis.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This multicenter, placebo-controlled randomized clinical trial was conducted at 11 sites in China between July 18, 2019, and January 15, 2023. Community-dwelling patients with inflammatory knee OA with effusion-synovitis on magnetic resonance imaging were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="UNASSIGNED">Participants were randomly assigned (1:1) to receive methotrexate, up to 15 mg weekly, or placebo using block randomization, stratified by study site.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcomes were knee visual analog scale (VAS) pain change and effusion-synovitis maximal area change, over 52 weeks in the intention-to-treat population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 278 participants screened, 215 participants (mean [SD] age, 60.4 [7.4] years; 191 [89%] female) were randomized (108 to the methotrexate group; 107 to the placebo group), and 175 (81%) completed the trial. Changes in VAS pain and effusion-synovitis maximal area were not significantly different between the methotrexate and placebo group over 52 weeks (between-group difference, 0.3 mm [95% CI, -6.7 to 7.3 mm] for VAS pain; 0.1 cm2 [95% CI, -0.8 to 1.0 cm2] for effusion-synovitis maximal area). No significant between-group differences were found for any of the prespecified secondary outcomes. At least 1 adverse event occurred in approximately 32 participants (29.6%) in the methotrexate group and 26 participants (24.3%) in the placebo group.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">The results of this randomized clinical trial show that, compared to placebo, low-dose methotrexate did not reduce pain or effusion-synovitis over 52 weeks in patients with knee OA and effusion-synovitis.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT03815448.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhaohua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Musculoskeletal Health and Royal North Shore Hospital, Kolling Institute, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Qinghong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical Collage Hospital, Chinese Academy of Medical Science; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jianhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Limin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Joint and Trauma Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Cibo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Beijing Hospital Affiliated to the National Health Commission, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Allergy, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tianwang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Guangdong Second People's Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Yifang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Shenzhen Third People's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Meihua</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Central People's Hospital of Zhanjiang, Zhanjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Allergy, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yingjuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Beijing Hospital Affiliated to the National Health Commission, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaotong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Qiuju</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Allergy, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Joint and Trauma Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zetao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Shenzhen Third People's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Guangdong Second People's Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lixia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Central People's Hospital of Zhanjiang, Zhanjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaoni</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Weiyu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Guangfeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Centre, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Peihua</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Peichun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haowei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicuttini</LastName><ForeName>Flavia M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Musculoskeletal Health and Royal North Shore Hospital, Kolling Institute, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical Collage Hospital, Chinese Academy of Medical Science; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Changhai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Centre, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03815448</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Intern Med. 2025 Jul 1;185(7):816-817. doi: 10.1001/jamainternmed.2025.1377.</RefSource><PMID Version="1">40455439</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="Y">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020370" MajorTopicYN="Y">Osteoarthritis, Knee</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013585" MajorTopicYN="Y">Synovitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hunter reported providing consulting advice on scientific advisory boards for Pfizer, Lilly, Haleon, TLCBio, Novartis, Tissuegene, Biobone, Sanofi, and Enlivex outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40455462</ArticleId><ArticleId IdType="pmc">PMC12131170</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2025.1359</ArticleId><ArticleId IdType="pii">2834774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duong V, Oo WM, Ding C, Culvenor AG, Hunter DJ. Evaluation and treatment of knee pain: a review. JAMA. 2023;330(16):1568-1580. doi: 10.1001/jama.2023.19675</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.19675</ArticleId><ArticleId IdType="pubmed">37874571</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Jones G, Cicuttini F, et al. Effect of vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial. JAMA. 2016;315(10):1005-1013. doi: 10.1001/jama.2016.1961</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.1961</ArticleId><ArticleId IdType="pubmed">26954409</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDO; GBD 2021 Osteoarthritis Collaborators . Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(23)00163-7</ArticleId><ArticleId IdType="pmc">PMC10477960</ArticleId><ArticleId IdType="pubmed">37675071</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175. doi: 10.1136/bjsports-2016-097333</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2016-097333</ArticleId><ArticleId IdType="pubmed">29018060</ArticleId></ArticleIdList></Reference><Reference><Citation>Roemer FW, Kassim Javaid M, Guermazi A, et al. Anatomical distribution of synovitis in knee osteoarthritis and its association with joint effusion assessed on non-enhanced and contrast-enhanced MRI. Osteoarthritis Cartilage. 2010;18(10):1269-1274. doi: 10.1016/j.joca.2010.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2010.07.008</ArticleId><ArticleId IdType="pubmed">20691796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dainese P, Wyngaert KV, De Mits S, Wittoek R, Van Ginckel A, Calders P. Association between knee inflammation and knee pain in patients with knee osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2022;30(4):516-534. doi: 10.1016/j.joca.2021.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2021.12.003</ArticleId><ArticleId IdType="pubmed">34968719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Blizzard L, Halliday A, et al. Association between MRI-detected knee joint regional effusion-synovitis and structural changes in older adults: a cohort study. Ann Rheum Dis. 2016;75(3):519-525. doi: 10.1136/annrheumdis-2014-206676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206676</ArticleId><ArticleId IdType="pubmed">25550336</ArticleId></ArticleIdList></Reference><Reference><Citation>Conaghan PG, D&#x2019;Agostino MA, Le Bars M, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010;69(4):644-647. doi: 10.1136/ard.2008.099564</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.099564</ArticleId><ArticleId IdType="pubmed">19433410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LA, Tan AL, Tanner SF, et al. Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment. Arthritis Rheum. 2004;50(8):2428-2432. doi: 10.1002/art.20444</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20444</ArticleId><ArticleId IdType="pubmed">15334454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenham CY, Grainger AJ, Hensor EM, Caperon AR, Ash ZR, Conaghan PG. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford). 2013;52(5):888-892. doi: 10.1093/rheumatology/kes386</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes386</ArticleId><ArticleId IdType="pubmed">23300331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingsbury SR, Tharmanathan P, Keding A, et al. Pain reduction with oral methotrexate in knee osteoarthritis: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2024;177(9):1145-1156. doi: 10.7326/M24-0303</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M24-0303</ArticleId><ArticleId IdType="pubmed">39074374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jones G, Keen HI, et al. Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial. Lancet. 2023;402(10414):1764-1772. doi: 10.1016/S0140-6736(23)01572-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01572-6</ArticleId><ArticleId IdType="pubmed">37839420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrero S, Wittoek R, Allado E, et al. Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial. Semin Arthritis Rheum. 2021;51(4):831-838. doi: 10.1016/j.semarthrit.2021.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2021.04.016</ArticleId><ArticleId IdType="pubmed">34157578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Yu Q, Leng X, et al. Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis?&#x2014;study protocol for a randomised, double-blind, and placebo-controlled trial. Trials. 2020;21(1):795. doi: 10.1186/s13063-020-04687-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04687-3</ArticleId><ArticleId IdType="pmc">PMC7493135</ArticleId><ArticleId IdType="pubmed">32938470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao C, Chen S, Gu Y, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J (Engl). 2003;116(8):1228-1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">12935395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan K, Zhang Y, Han L, et al. Safety and efficacy of methotrexate for Chinese adults with psoriasis with and without psoriatic arthritis. JAMA Dermatol. 2019;155(3):327-334. doi: 10.1001/jamadermatol.2018.5194</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2018.5194</ArticleId><ArticleId IdType="pmc">PMC6440263</ArticleId><ArticleId IdType="pubmed">30698628</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA. Folic acid supplementation for rheumatoid arthritis patients on methotrexate: the good gets better. Cochrane Database Syst Rev. 2013;2013(7):ED000063. doi: 10.1002/14651858.ED000063</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.ED000063</ArticleId><ArticleId IdType="pmc">PMC10846356</ArticleId><ArticleId IdType="pubmed">24151647</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Blizzard L, Jin X, et al. Quantitative assessment of knee effusion-synovitis in older adults: association with knee structural abnormalities. Arthritis Rheumatol. 2016;68(4):837-844. doi: 10.1002/art.39526</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39526</ArticleId><ArticleId IdType="pubmed">26636246</ArticleId></ArticleIdList></Reference><Reference><Citation>Han W, Aitken D, Zhu Z, et al. Signal intensity alteration in the infrapatellar fat pad at baseline for the prediction of knee symptoms and structure in older adults: a cohort study. Ann Rheum Dis. 2016;75(10):1783-1788. doi: 10.1136/annrheumdis-2015-208360</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208360</ArticleId><ArticleId IdType="pubmed">26612337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004;12(5):389-399. doi: 10.1016/j.joca.2004.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2004.02.001</ArticleId><ArticleId IdType="pubmed">15094138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Jin X, Blizzard L, et al. Associations between knee effusion-synovitis and joint structural changes in patients with knee osteoarthritis. J Rheumatol. 2017;44(11):1644-1651. doi: 10.3899/jrheum.161596</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161596</ArticleId><ArticleId IdType="pubmed">28864651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates, Inc, Publishers; 1988.</Citation></Reference><Reference><Citation>Laslett LL, Dor&#xe9; DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71(8):1322-1328. doi: 10.1136/annrheumdis-2011-200970</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200970</ArticleId><ArticleId IdType="pubmed">22355040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellamy N, Bell MJ, Goldsmith CH, et al. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis. 2005;64(6):881-885. doi: 10.1136/ard.2004.026443</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.026443</ArticleId><ArticleId IdType="pmc">PMC1755531</ArticleId><ArticleId IdType="pubmed">15564311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosta PE, Voulgari PV, Zikou AK, Tsampoulas K, Drosos AA, Argyropoulou MI. Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. Scand J Rheumatol. 2012;41(5):339-344. doi: 10.3109/03009742.2012.666263</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.666263</ArticleId><ArticleId IdType="pubmed">22646866</ArticleId></ArticleIdList></Reference><Reference><Citation>Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15(6):355-363. doi: 10.1038/s41584-019-0221-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0221-y</ArticleId><ArticleId IdType="pubmed">31068673</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini EH, Brewer EJ, Kuzmina N, et al. ; The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children&#x2019;s Study Group . Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326(16):1043-1049. doi: 10.1056/NEJM199204163261602</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199204163261602</ArticleId><ArticleId IdType="pubmed">1549149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD000951. doi: 10.1002/14651858.CD000951</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD000951</ArticleId><ArticleId IdType="pubmed">10796393</ArticleId></ArticleIdList></Reference><Reference><Citation>National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital); Chinese Association of Rheumatology and Immunology Physicians; Rheumatology and Immunology Professional Committee of Chinese Rehabilitation Medical Association; Rheumatology and Immunology Professional Committee of Chinese Research Hospital Association; Rheumatology and Immunology Branch of Beijing Association of Holistic Integrative Medicine . 2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 2024;63(11):1059-1077. doi: 10.3760/cma.j.cn112138-20240531-00360</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112138-20240531-00360</ArticleId><ArticleId IdType="pubmed">39482070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kameda H, Fujii T, Nakajima A, et al. ; Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis . Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31-40. doi: 10.1080/14397595.2018.1472358</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1472358</ArticleId><ArticleId IdType="pubmed">29718746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Liu Z, Chen J, Wang X, Jiao Z, Wang Z. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review. Eur J Clin Pharmacol. 2024;80(1):11-37. doi: 10.1007/s00228-023-03579-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-023-03579-0</ArticleId><ArticleId IdType="pubmed">37934204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30363-4</ArticleId><ArticleId IdType="pubmed">27287832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>